DEALS: J&J buys Pfizer's OTC division for $16.6B

DEALS

WHO

WITH

WHAT

SCOOP

Pfizer

Johnson & Johnson

$16.6B sale

Pfizer has sold its OTC division to J&J for $16.6 billion in cash.

Siemens

Bayer Healthcare

$5.3B buyout

Siemens has purchased the diagnostics division of Bayer Healthcare. The move is expected to help Bayer complete the acquisition of Schering.

Barr Pharmaceuticals

Pliva

$2.2B buyout

Barr Pharmaceuticals beat out Actavis Group when generic drug maker Pliva announced that it accepted Barr's $2.2 billion buyout offer.

Johnson & Johnson

Vertex

Collaboration deal

The companies will collaborate to develop VX-950 for hepatitis C. Vertex gains $165 million and up to $380 million in milestone payments.

Takeda

Affymax

$535M deal

Takeda will pay Affymax up to $535 million for the worldwide rights--excluding Japan--to Hematide, a therapy for anemia in cancer and kidney disease patients.

Sanofi-Aventis

Taiho

$360M deal

The deal is for most of the global rights to Taiho's S-1 cancer therapy for colorectal, head and neck cancer

Johnson & Johnson

Metabolex

Licensing deal

Johnson & Johnson is buying into Metabolex's program for diabetes and other metabolic conditions with a new collaboration pact that provides a $40 million equity stake and up to $508 million in milestones.

Mayne Pharma

SuperGen

Licensing deal

Mayne has bought North American rights to the leukemia drug Nipent and a medical surface cleaner from SuperGen for $15 million up front and up to $19 million in milestone payments.

Skyepharma

Mundipharma International Holdings

$5M licensing deal

Skyepharma bought back European rights to DepoBupivacaine for its experimental pain drug DepoBupivacaine.

Eli Lilly

Inpharmatica

Licensing deal

Eli Lilly has licensed Admensa Interactive, Inpharmatica's suite of predictive drug absorption, distribution, metabolism and excretion (ADME) models and compound prioritization tools.